ArticleCureus2025
High Source Strength of Most Blister Packs Delivered for 125I Seed Brachytherapy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the beginning of 125I seed brachytherapy, our facility has verified the source strength of all blister packs delivered. We set a reference range based on measurements taken with a well-type ionization chamber. There are scattered reports on verification for the purpose of detecting dead seeds, but to our knowledge, there are no reports on the application of source strength verification results in actual clinical practice for deviations of a few percent below the intervention value. In this case, five of the six TheraAgX100 (Theragenics Corporation, Buford, GA, USA) blister packs delivered had a source strength that was 3-5% stronger than the nominal value. We report on this case, in which we consulted with the physician regarding the placement of the source, taking into consideration the measured source strength, which led to a safer treatment. We used VariSeed 9.0 (Varian Medical Systems Co., Ltd., Palo Alto, CA, USA), a treatment planning system (TPS), with a nominal value of 0.274 mCi and a nominal value of 0.288 mCi, which is 5% stronger than the nominal value for safety reasons, and verified the difference in prescribed doses for planning target volume (PTV) and organ at risk (OAR). We placed 0.288 mCi in areas where the distance from the urethra and rectum, which are susceptible to adverse events, could be ensured. When comparing the nominal value and measured value of the prescribed dose, the measured value of PTV D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.